跳到正文
← 返回论文列表与筛选
阅读说明

本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。

DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。

本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。

引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。

关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。

分类依据与纠错

AI 根据所提供的论文材料归类:摘要围绕临床试验中经自适应亚群选择后的处理效应估计及其选择偏差展开。

反馈分类问题

正在核对关联版本…

代码、数据与补充材料

正在核对对应版本的资源…

关注这篇论文的作者
Enyu Li
Nigel Stallard
Ekkehard Glimm
Peter K. Kimani

两阶段自适应富集设计中的无偏估计

研究问题
临床试验依据中期结果选择受益亚群后,如何纠正处理效应的选择偏差,并使估计框架适用于更广泛的亚群选择规则?
方法与思路
作者以样本空间划分条件定义一类选择规则,系统推导统一的条件无偏估计公式,目标是获得条件下方差最小的估计量。
材料陈述的贡献
摘要称统一公式覆盖多种自适应富集设计,减少逐项推导的需要,并通过模拟展示所提 UMVCUE 的无偏表现。
阅读关注点
应核对选择规则的样本空间划分条件、条件化事件与目标参数,以及最小方差结论所需模型条件和区间推断处理。
阅读边界
这是 arXiv 预印本,评审与接收未核实;摘要未说明具体分布假设、规则覆盖边界及模拟细节,无偏性不能任意外推。

原文摘要

Recent advances in biomedical research have identified an increasing number of biomarkers associated with heterogeneity in patient responses to medical treatments. When a treatment is suspected to benefit certain patient subpopulations, adaptive enrichment designs may be more efficient and ethical. In such designs, an interim analysis is incorporated during the trial to select patient subpopulations for which the experimental treatment appears promising, according to predefined subpopulation selection rules. However, data-dependent selection can induce selection bias, causing conventional maximum likelihood estimators (MLEs) to overestimate the treatment effect in the selected patient subgroup. Existing inference methods for addressing this bias are typically rule-specific, highlighting the need for an estimation framework that accommodate a broader class of subpopulation selection rules. In this work, we define a general class of subpopulation selection rules based on the sample space partition condition and provide a systematic derivation that yields a unified formula for the Uniformly Minimum Variance Conditional Unbiased Estimator (UMVCUE). This generality allows our formulation to encompass a wide spectrum of adaptive enrichment designs, eliminating the necessity for case-specific derivations for each new design. Extensive simulations confirm the unbiasedness of the proposed UMVCUE, ensuring that therapeutic benefits are not overestimated. By bridging the gap between flexible interim subpopulation selection and rigorous statistical inference, our framework has the potential to facilitate the implementation of diverse subpopulation selection rules with greater ease in real-world trials and promote more efficient and ethical drug development.

笔记与分组
相关领域论文